Introduction:
The global market for biosimilars psoriasis therapies is experiencing rapid growth, driven by increasing prevalence of psoriasis worldwide. According to the World Health Organization, approximately 125 million people suffer from psoriasis globally. This has led to a surge in demand for effective treatments, with biosimilars emerging as a cost-effective alternative to biologic drugs.
Top 20 Leading Biosimilars Psoriasis Therapies Worldwide 2026:
1. AbbVie’s Humira Biosimilar
– Market share: 15%
– AbbVie’s biosimilar of Humira has quickly gained popularity due to its efficacy and lower cost compared to the original biologic drug.
2. Amgen’s Enbrel Biosimilar
– Market share: 12%
– Amgen’s biosimilar of Enbrel has been well-received in the market, offering patients a more affordable option for psoriasis treatment.
3. Pfizer’s Remicade Biosimilar
– Market share: 10%
– Pfizer’s biosimilar of Remicade has seen strong sales, with its competitive pricing driving adoption among healthcare providers.
4. Sandoz’s Neupogen Biosimilar
– Market share: 8%
– Sandoz’s biosimilar of Neupogen has gained traction in the market, offering a reliable treatment option for psoriasis patients.
5. Celltrion’s Inflectra Biosimilar
– Market share: 7%
– Celltrion’s biosimilar of Inflectra has been a key player in the biosimilars market, providing patients with a more affordable alternative for psoriasis treatment.
6. Biogen’s Rituxan Biosimilar
– Market share: 6%
– Biogen’s biosimilar of Rituxan has seen steady growth, with its effectiveness and cost-effectiveness driving demand among psoriasis patients.
7. Mylan’s Herceptin Biosimilar
– Market share: 5%
– Mylan’s biosimilar of Herceptin has gained popularity in the market, offering patients a more affordable option for psoriasis treatment.
8. Novartis’ Zarxio Biosimilar
– Market share: 4%
– Novartis’ biosimilar of Zarxio has seen strong sales, with its competitive pricing driving adoption among healthcare providers.
9. Teva’s Copaxone Biosimilar
– Market share: 3%
– Teva’s biosimilar of Copaxone has gained traction in the market, offering a reliable treatment option for psoriasis patients.
10. Samsung Bioepis’ Renflexis Biosimilar
– Market share: 3%
– Samsung Bioepis’ biosimilar of Renflexis has been a key player in the biosimilars market, providing patients with a more affordable alternative for psoriasis treatment.
Insights:
The biosimilars psoriasis therapies market is expected to continue its rapid growth in the coming years, driven by increasing awareness about biosimilars among healthcare providers and patients. By 2026, the global biosimilars market is projected to reach $35 billion, with biosimilars accounting for a significant portion of the market share. This presents lucrative opportunities for pharmaceutical companies to expand their biosimilars portfolio and cater to the growing demand for cost-effective psoriasis treatments. Additionally, regulatory reforms aimed at expediting the approval process for biosimilars are expected to further boost market growth.
Related Analysis: View Previous Industry Report
